ORBA Wealth Advisors L.L.C. Sells 403 Shares of Johnson & Johnson (NYSE:JNJ)

ORBA Wealth Advisors L.L.C. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 15.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,137 shares of the company’s stock after selling 403 shares during the period. ORBA Wealth Advisors L.L.C.’s holdings in Johnson & Johnson were worth $312,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in JNJ. Eagle Strategies LLC boosted its position in shares of Johnson & Johnson by 1.8% during the 4th quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock worth $563,000 after acquiring an additional 63 shares in the last quarter. Alliance Wealth Advisors LLC UT boosted its holdings in Johnson & Johnson by 1.4% in the fourth quarter. Alliance Wealth Advisors LLC UT now owns 4,714 shares of the company’s stock valued at $739,000 after purchasing an additional 64 shares in the last quarter. Carolinas Wealth Consulting LLC increased its stake in Johnson & Johnson by 0.4% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock valued at $2,643,000 after purchasing an additional 64 shares during the last quarter. Adamsbrown Wealth Consultants LLC increased its stake in Johnson & Johnson by 2.3% in the fourth quarter. Adamsbrown Wealth Consultants LLC now owns 2,879 shares of the company’s stock valued at $451,000 after purchasing an additional 65 shares during the last quarter. Finally, Verity Asset Management Inc. increased its stake in Johnson & Johnson by 2.0% in the fourth quarter. Verity Asset Management Inc. now owns 3,268 shares of the company’s stock valued at $512,000 after purchasing an additional 65 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 8th. TD Securities decreased their price objective on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Morgan Stanley increased their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Finally, Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded up $0.25 during midday trading on Wednesday, reaching $158.64. The company’s stock had a trading volume of 2,214,946 shares, compared to its average volume of 7,338,182. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.39. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock’s 50 day simple moving average is $151.63 and its 200 day simple moving average is $153.06. The firm has a market capitalization of $381.80 billion, a PE ratio of 9.89, a P/E/G ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the business posted $2.80 earnings per share. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.13%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.